Your Trusted Guide to Psilocybin
& Magic Mushrooms
Evidence-based guides, harm-reduction tools, and a verified directory of psychedelic churches — all free.
Start here
Essential guides
Psilocybin Therapy
The three-phase protocol, what the trials show, and how legal access works in Oregon and Colorado.
Read guide →Safe Trip Guide
Set, setting, preparation, navigating hard moments, and the integration period that follows.
Read guide →Microdosing Guide
Schedules, dose ranges, and what published studies do (and do not) support for microdosing.
Read guide →VA Psilocybin Trial, Final FDA Guidance, and AI in Trials — August 2026
In one week the VA launched a five-site COMP360 trial for veterans, FDA finalized psychedelic clinical-investigation guidance and set a September 14 hearing, and ICON hired Anthropic’s Claude for trial operations.
Read the full breakdown →Dosage calculator, calibrated to published studies.
Body-weight adjusted ranges for dried P. cubensis, drawn from Johns Hopkins and Imperial College protocols. Start low. Potency varies ±30% between specimens — always titrate, never stack.
Educational estimate only. Not medical advice. Always start lower than calculated, and know your source.
Evidence by condition
Psilocybin for mental health
Depression
Treatment-resistant and major depression. The COMP360 program and what comes next for real-world access.
Alcohol Use Disorder
Reductions in heavy-drinking days reported in published trials, and how the facilitated protocol is structured.
End-of-Life Anxiety
Palliative settings showing rapid, durable reductions in existential distress under well-characterized protocols.
PTSD
How psilocybin research is positioned alongside other trauma therapies, and the open questions that remain.
OCD
Small studies suggesting reduced intrusive thoughts. Trials are underway but not yet powered for efficacy claims.
Cluster Headaches
Observational reports of "breaking the cycle." Dose-response is not yet characterized in a controlled setting.
Directory
Common psilocybin-active species
Psilocybe cubensis
Well-StudiedBehind most cultivars and the vast majority of clinical trials. Effects are better documented than for rarer species.
Psilocybe semilanceata
Some DataSmall and potent, common in temperate pasture. Less trial data than cubensis but extensively used historically.
Psilocybe azurescens
Limited DataVery potent; Pacific Northwest native. Treat potency and set/setting with extra care — easy to overshoot.
Psilocybe cyanescens
Some DataPNW and European. Fruits on wood chips in cool months. Potency variable between patches; start lower than expected.
Psilocybe mexicana
Well-StudiedHistorical Mesoamerican ceremonial species. Milder than cubensis, extensively studied in ethnobotany literature.
Psilocybe baeocystis
Limited DataPNW native. Limited modern data; potency reports inconsistent. Identification is tricky for beginners.
From the desk of PsyBear Editorial
Latest research & analysis
Puerto Rico Ordered a Psychedelic Research Pilot — Not a Clinic
Governor González-Colón signed EO 2026-037 to study whether Puerto Rico can host trials of ibogaine, psilocybin, and MDMA. Veterans are named first. The order does not legalize ...
This Is Your Brain on Psilocybin — The New Clinical Evidence
Psychiatrist Dr. Tracey Marks explains how a clinical psilocybin dose can quiet rumination, reopen a plasticity window, and why that is not the same thing as...
What a Heroic Dose of Psilocybin Means — According to Johns Hopkins
Johns Hopkins professor Matthew Johnson explains why a 30–40mg “heroic dose” of psilocybin can feel life-changing — and why the container around it matters m...
Get the weekly research digest.
Join free for our weekly research digest, plus community updates and harm-reduction news. One email a week — no spam.